STE STERIS Plc

STERIS Expands Healthcare Consumables Offering with Acquisition of Key Surgical for approximately $850 million

STERIS Expands Healthcare Consumables Offering with Acquisition of Key Surgical for approximately $850 million
EN
06/10/2020

Underlying

STESTERIS Plc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STERIS Plc

 PRESS RELEASE
Free
STE STERIS PLC

STERIS Announces Financial Results for Fiscal 2026 Third Quarter

STERIS Announces Financial Results for Fiscal 2026 Third Quarter Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion comp...

February 4, 2026 1 EN
 PRESS RELEASE
Free
STE STERIS PLC

STERIS Announces Dividend of $0.63 per share

STERIS Announces Dividend of $0.63 per share DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at -ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection...

January 28, 2026 1 EN
 PRESS RELEASE
Free
STE STERIS PLC

STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results...

STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026 DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the ...

January 21, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.31
ILMN ILLUMINA INC.
WAT Waters Corporat... ... (+28)

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

ILMN ILLUMINA INC.
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
11/25/25 November 25, 2025 1 EN
 PRESS RELEASE
Free
STE STERIS PLC

STERIS Announces Financial Results for Fiscal 2026 Second Quarter 

STERIS Announces Financial Results for Fiscal 2026 Second Quarter  Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the ...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch